Nifty Midcap 50 Index Funds Offer Growth Access to Mid-Sized Companies

Mutual funds that track the Nifty Midcap 50 Index are gaining attention as investment vehicles that give investors exposure to mid-sized companies showing strong growth potential. These funds combine several...
This story originally appeared on Due
Mutual funds that track the Nifty Midcap 50 Index are gaining attention as investment vehicles that give investors exposure to mid-sized companies showing strong growth potential. These funds combine several key advantages for investors looking to expand their portfolios beyond large-cap stocks.
The Nifty Midcap 50 Index represents a collection of medium-sized Indian companies that sit between small emerging businesses and established large corporations. These companies often demonstrate more growth potential than their larger counterparts while offering more stability than smaller firms.
Key Benefits for Investors
Investors choosing mutual funds that track the Nifty Midcap 50 Index gain several advantages. First, these funds provide instant diversification across 50 different mid-sized companies, spreading risk across multiple sectors and businesses.
Professional management is another significant benefit. Fund managers handle the complex tasks of tracking the index, rebalancing the portfolio when needed, and managing inflows and outflows of capital—tasks that would be time-consuming for individual investors.
Cost efficiency stands out as a third major advantage. Index-tracking funds typically charge lower expense ratios compared to actively managed funds, allowing investors to keep more of their returns. This cost advantage compounds over time, potentially leading to better long-term performance.
Growth Characteristics of Mid-Cap Companies
Mid-cap companies often occupy a sweet spot in the market. They've typically moved beyond the high-risk early stages of business development but still have substantial room to grow compared to large-cap corporations.
These companies frequently demonstrate several attractive characteristics:
Higher growth rates than large-cap companies
More established business models than small-caps
Greater flexibility to adapt to changing market conditions
Potential to become tomorrow's large-cap leaders
Market Performance and Considerations
The Nifty Midcap 50 Index has shown periods of outperformance compared to broader market indices, though this comes with increased volatility. Investors should recognize that mid-cap stocks can experience sharper price swings during market downturns.
'Mid-cap funds offer growth potential that can complement existing large-cap holdings,' financial analysts note, pointing to the diversification benefits these funds provide in a well-balanced portfolio.
For investors with medium to long-term horizons, these funds may provide an opportunity to capture growth in companies that are established enough to have proven business models but still small enough to have significant expansion potential.
Investment Strategy Implications
Financial advisors often recommend that investors consider their overall asset allocation when adding mid-cap exposure. These funds typically work best as part of a diversified strategy rather than as standalone investments.
The ideal allocation to mid-cap funds varies based on an investor's risk tolerance, time horizon, and financial goals. Younger investors with longer time horizons might allocate a larger percentage to mid-caps, while those nearing retirement might maintain smaller positions.
Regular rebalancing is also important when including these funds in a portfolio, as their performance can sometimes lead to unintended shifts in overall asset allocation.
As with any investment, potential investors should review the specific fund's tracking error, expense ratio, and historical performance before making decisions. While past performance doesn't guarantee future results, these metrics can provide insight into how well a fund fulfills its stated objective of tracking the Nifty Midcap 50 Index.
The post Nifty Midcap 50 Index Funds Offer Growth Access to Mid-Sized Companies appeared first on Due.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

38 minutes ago

• Yahoo

5 AI stocks to consider buying and holding for the long term

Many AI applications are still in development, offering ground-floor buying opportunities in their stocks. Below are some established companies that five of contract writers like as investments to consider buying to capitalise on this transformational technology. What it does: Alphabet is a global technology company best known for Google, YouTube, Android, and cloud services. By Mark Hartley. When considering an AI investment for the long term, Google's parent company Alphabet (NASDAQ: GOOG) stands out. It has emerged as a key player in the AI space, leveraging its vast data resources and computational power to dig deep roots into the industry. Through DeepMind and its Gemini AI models, Alphabet is at the forefront of generative AI development. Google Cloud offers scalable AI tools and infrastructure for businesses, while AI enhancements in products like Search, Gmail, and YouTube are well-positioned to benefit from advertising revenue. Alphabet's expansive ecosystem gives it a strategic advantage in training and deploying AI models at scale. A significant risk, however, lies in the potential disruption of its core search business. As AI chatbots and generative search become more prevalent, traditional search advertising could face margin pressure. Additionally, if faces increased regulatory scrutiny on data usage, antitrust concerns and competition from rivals like Microsoft and Amazon. Mark Hartley doesn't own shares in any of the stocks mentioned. What it does: Cellebrite is the global leader in decrypting mobile phones and other devices supporting digital forensic investigations. By Zaven Boyrazian. Many AI stocks today are unproven. That's why I prefer established players leveraging AI to improve their existing mission-critical products like Cellebrite (NASDAQ:CLBT). Cellebrite specialises in extracting encrypted data from mobile phones and other devices aiding law enforcement and enterprises in criminal and cybersecurity investigations. Over 90% of crime commited today has a digital element. And when it comes to decrypting mobile phones, Cellebrite is the global gold standard. The company is now leveraging AI to analyse encrypted data – drastically accelerating a task that's historically been increadibly labour intensive identifying patterns, discovering connections, and establishing leads. Most of Cellebrite's revenue comes from law enforcement, exposing Cellebrite to the risk of budget cuts. In fact, fears of lower US federal spending is why the stock dropped sharply in early 2025. And with a premium valuation, investors can expect more volatility moving forward. But in the long run, Cellebrite has what it takes to be an AI winner in my mind. That's why I've already bought shares. Zaven Boyrazian owns shares in Cellebrite. What it does: Dell Technologies provides a broad range of IT products and services and is an influential player in AI. By Royston Wild. Dell Technologies (NYSE:DELL) isn't one of the more fashionable names in the realm of artificial intelligence (AI). The good news is that this means it trades at a whopping discount to many of its peers. For this financial year (to January 2026), City analysts think earnings will soar 41% year on year, leaving it on a price-to-earnings (P/E) multiple of 12.6 times. Such readings are as rare as hen's teeth in the high-growth tech industry. In addition, Dell shares also trade on a price-to-earnings growth (PEG) ratio of 0.3 for this year. Any reading below 1 implies a share is undervalued. These modest readings fail to reflect the exceptional progress the company's making in AI, in my opinion. Indeed, Dell last month raised guidance for the current quarter as it announced 'unprecedented demand for our AI-optimised servers' during January-March. It booked $12.1bn in AI orders in the last quarter alone, beating the entire total for the last financial year. Dell is a major supplier of server infrastructure that let Nvidia's high-power chips do their thing. Dell's shares could sink if unfavourable developments in the ongoing tariff wars transpire. But the company's low valuation could help limit the scale of any falls. Royston Wild does not own shares in Dell or Nvidia. What it does: Salesforce is a customer relationship management (CRM) software company that is developing AI agents. By Edward Sheldon, CFA. We've all seen the potential of artificial intelligence (AI) in recent years. Using apps like ChatGPT and Gemini, we can do a lot of amazing things today. These apps are just the start of the AI story, however. I expect the next chapter to be about AI agents – software programmes that can complete tasks autonomously and increase business productivity exponentially. One company that is active in this space is Salesforce (NYSE: CRM). It's a CRM software company that has recently developed an agentic AI offering for businesses called 'Agentforce'. It's still early days here. But already the company is having a lot of success with this offering, having signed up 8,000 customers since the product's launch last October. Now, Salesforce is not the only company developing AI agents. So, competition from rivals is a risk. I like the fact that the company's software is already embedded in over 150,000 organisations worldwide though. This could potentially give it a major competitive advantage in the agentic AI race. Edward Sheldon has positions in Salesforce. What it does: Salesforce is a cloud-based software company specialising in customer relationship management, helping businesses manage sales, marketing, support, and data. By Ben McPoland. I think Salefsforce (NYSE: CRM) looks well set up to benefit in the age of AI. Specifically, its Agentforce platform, which lets businesses deploy AI agents to handle various tasks, could be the company's next big growth engine. By the end of April, it had already closed over 8,000 deals, just six months after launching Agentforce. Half of those were paid deals, taking its combined data cloud and AI annual recurring revenue above $1bn. Granted, that looks like small potatoes set against the $41.2bn in sales it's expected to generate this fiscal year. But it's still very early days, and management reckons the digital labour market opportunity could run into the trillions of dollars. Of course, it's always best to treat such mind-boggling projections with a healthy dose of scepticism. And the company does face stiff competition in the AI agent space, especially from Microsoft and ServiceNow. Nevertheless, I'm bullish here. Salesforce is already deeply embedded in sales, service, and marketing. Its AI agents slot into existing workflows, which I think will prove to be a big advantage over unproven AI upstarts. Ben McPoland owns shares of Salesforce. The post 5 AI stocks to consider buying and holding for the long term appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. The Motley Fool UK has recommended Alphabet, Amazon, Cellebrite, Microsoft, Nvidia, and Salesforce. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Associated Press

42 minutes ago

• Associated Press

Octa's oil outlook: Middle East tensions threaten global supply

KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 21 June 2025 - Crude oil, which is arguably the world's most important commodity, is on everybody's mind right now. The flared up conflict in the Middle East is increasing risks of a major oil supply shock, potentially pushing the price of 'black gold' into the stratosphere and completely derailing the global economy. In this article, Octa, a global retail broker, shares its expert opinion on the unfolding situation and outlines possible scenarios for the global oil market. Octa Broker As it often happens, the market started to price in the possibility of a new conflict in the Middle East well in advance. On 11 June, oil prices rose more than 4% after reports surfaced that the U.S. was preparing to evacuate its Iraqi embassy due to heightened security concerns in the region. Two days later, Israel and Iran exchanged airstrikes, pushing both Brent and West Texas Intermediate (WTI), the world's two major oil benchmarks, to five-month highs as investors anticipated potential supply disruptions from an open conflict. To this day, the conflict continues without resolution and oil prices remain elevated even as there are some telltale signs that the parties may be willing to negotiate. 'This burgeoning unrest introduces an unprecedented degree of volatility, significantly amplifying the specter of a catastrophic oil supply shock', argues Kar Yong Ang, a financial market analyst at Octa broker, adding that the conflict between Israel and Iran 'carries ominous potential to propel crude prices to unprecedented levels, thereby unleashing a cascade of detrimental effects that could, in the most dire of scenarios, cause a major global economic crisis'. Indeed, the Middle East in general and Iran in particular play a pivotal role in global energy markets. A substantial portion of the world's crude oil and liquified natural gas (LNG) is produced and exported in this region. Iran itself, despite the existing sanctions on exports, remains an important supplier of oil—notably, for China. Furthermore, a vast number of ships carrying crude oil and LNG transit through the Strait of Hormuz, a narrow yet vital chokepoint that Iran has repeatedly threatened to close. Should Iran act on this threat and block the strait, the repercussions would be quite severe, likely pushing global crude oil prices well above $100 per barrel, or even higher, due to the significant disruption of supply. Technically, if we look at a broader, long-term picture, WTI crude oil seems to be moving sideways with a minor bearish tilt. On a daily chart (see below), the price still has not escaped from the bearish parallel channel. However, due to the latest geopolitical news, the price has managed to rise above the 200-day moving average (MA) and seems poised to break above the critically important 77.60-78.00 area. 'Breaching the $80 handle should not be difficult if the current situation deteriorates sharply', says Kar Yong Ang. 'Continuing destruction of oil infrastructure in Iran, potential U.S. involvement in the war, countries' unwillingness to negotiate and, above all else, Iran's attempts to block the Strait of Hormuz, all of this will have a bullish impact on prices'. Indeed, a break above 80 level, would open the way towards 83.40, 85.20, 87.30, and 90.00 area. Alternatively, in case the hostilities moderate somewhat, other countries—particularly the U.S.—refrain from directly participating in the conflict, and both Israel and Iran express willingness to negotiate, bearish sentiment will immediately kick in. 'I think WTI oil may lose as much as 5 dollars per barrel in the blink of an eye should we see some progress in nuclear negotiations between Europeans and Iranians, which are due to commence in Geneva this Friday', concludes Kar Yong Ang. In this scenario, a break below 71.50 level would allow bears to target 67.80, 64.80 and 61.70. Overall, WTI crude price is now stuck in a broad range between $70 and $80. The move above and below these two levels will essentially indicate if the situation in the region is getting worse or is getting better. The chart below shows potential bullish and bearish targets, marked in green and red, respectively. NYMEX light sweet crude oil (WTI) daily chartSource: TradingView, Octa analysis and calculations ___ Disclaimer: This press release does not contain or constitute investment advice or recommendations and does not consider your investment objectives, financial situation, or needs. Any actions taken based on this content are at your sole discretion and risk—Octa does not accept any liability for any resulting losses or consequences. Hashtag: #Octa The issuer is solely responsible for the content of this announcement. Octa Octa

Associated Press

43 minutes ago

• Associated Press

SINOVAC Board of Directors Prevails Against Advantech/Prime's New York Lawsuit

BEIJING--(BUSINESS WIRE)--Jun 20, 2025-- SINOVAC Biotech Ltd. (NASDAQ: SVA) (' SINOVAC ' or the ' Company '), a leading provider of biopharmaceutical products in China, today announced it has prevailed against Advantech/Prime Success' ('Advantech/Prime') Petition for Emergency Injunctive Relief in the U.S. District Court for the Southern District of New York. The result in the New York court represents another failure in the campaign by Advantech/Prime in coordination with Vivo Capital (together known as the 'Dissenting Investor Group') to wrest control of SINOVAC from its recently installed, lawfully-elected Board of Directors (the 'current SINOVAC Board') in accordance with the Privy Council order and Antiguan Law, and to interfere with the payment of the US$55.00 per common share special cash dividend declared by the current SINOVAC Board. Following the New York court's ruling, the current SINOVAC Board is free to pursue its legal action in Antigua seeking to cancel the PIPE shares invalidly issued to the Dissenting Investor Group by the former illegitimate board (the 'Imposter Former Board'). If the current SINOVAC Board succeeds in legal proceedings on the PIPE shares, it has announced its intention to redistribute an additional US$11.00 per common share to SINOVAC's valid shareholders. Dr. Chiang Li, Chairman of the SINOVAC Board, commented, 'We will continue our mission to restore fairness and deliver value to all valid SINOVAC shareholders, starting with paying the $55.00 per share special cash dividend as soon as July 7, 2025.' The Dissenting Investor Group's self-serving, multi-pronged lawfare strategy against SINOVAC has one goal: to prevent all valid SINOVAC common shareholders from receiving any dividend payments unless the Dissenting Investor Group receives an allocation for their invalid PIPE shares, despite the fact that they have already received over US$1 billion in dividends from a SINOVAC operating subsidiary. The current SINOVAC Board has set aside in escrow the pro rata portion of dividends for the PIPE shares — funds the Dissenting Investor Group could receive if the legal proceedings they initiated rule in their favor. The current SINOVAC Board is fighting back – and winning. We feel certain that we will prevail against any further legal action by the Dissenting Investor Group and look forward to ensuring all valid shareholders receive their fair share. Your Vote is Important Your vote on or before July 8 will be about the future of SINOVAC, your receipt of your make-whole dividend payments in the near-term, and the long-term value of your investment. We urge you to keep SINOVAC's Board in place and vote on the WHITE proxy card ' AGAINST ' Proposal 1 to remove the current Board and ' AGAINST ' Proposal 2 to appoint the Reconstituted Imposter Board Slate. Your vote is critical to ensuring that SINOVAC remains on the path to stability, growth, and value creation for all shareholders. DISCARD any items you received asking you to vote for the Reconstituted Imposter Former Board Slate. If you have already voted for the Reconstituted Imposter Former Board Slate, you can subsequently revoke it by using the WHITE proxy card or WHITE voting instruction form to vote. Only your latest-dated vote will count! If you have questions about how your vote can be counted, please contact our proxy solicitor, Georgeson LLC, toll free at (844) 568-1506 in the U.S. and (646) 543-1968 outside the U.S. or via email at [email protected]. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under 'Category 1 Preventative Biological Products' and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Important Additional Information and Where to Find It In connection with SINOVAC's Special Meeting, SINOVAC has filed with the U.S. Securities and Exchange Commission ('SEC') and mailed to shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a WHITE proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and other interested parties will be able to obtain the documents free of charge at the SEC's website, or from SINOVAC at its website: You may also obtain copies of SINOVAC's definitive proxy statement and other documents, free of charge, by contacting SINOVAC's Investor Relations Department at [email protected]. Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'potential,' 'continue,' 'is/are likely to' or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's or Board's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law. View source version on CONTACT: Investor and Media Contact FGS Global [email protected] KEYWORD: CHINA UNITED STATES NORTH AMERICA ASIA PACIFIC NEW YORK INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH SOURCE: The Board of Directors of Sinovac Biotech Ltd. Copyright Business Wire 2025. PUB: 06/20/2025 10:56 PM/DISC: 06/20/2025 10:55 PM